Pfizer (PFE) Deferred Taxes (2009 - 2026)
Pfizer (PFE) posted quarterly Deferred Taxes of -$12.0 million for Q1 2026, up 98.19% year-over-year from -$6.1 million in Q1 2025, and up 97.23% quarter-over-quarter from -$433.0 million in Q4 2025.
Pfizer (PFE) Deferred Taxes (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Deferred Taxes for 18 consecutive years, with -$12.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Deferred Taxes rose 98.19% year-over-year to -$12.0 million; the TTM figure through Mar 2026 stood at -$1.5 billion (up 58.75% YoY), while the FY2025 annual figure was -$2.1 billion, down 1.47% from the prior year.
- Deferred Taxes advanced to -$12.0 million in Q1 2026 per PFE's latest filing, from -$433.0 million in the prior quarter.
- Across five years, Deferred Taxes topped out at -$12.0 million in Q1 2026 and bottomed at -$2.3 billion in Q2 2022.
- Historically, Deferred Taxes has averaged -$912.7 million across 5 years, with a median of -$765.0 million in 2025.
- Annual changes were most pronounced in 2022 — Deferred Taxes sank 1627.27% — and 2026, when it jumped 98.19%.
- Pfizer's Deferred Taxes stood at -$1.1 billion in 2022, then slumped by 62.98% to -$1.9 billion in 2023, then grew by 8.18% to -$1.7 billion in 2024, then surged by 74.62% to -$433.0 million in 2025, then surged by 97.23% to -$12.0 million in 2026.
- Business Quant data shows PFE's Deferred Taxes at -$12.0 million in Q1 2026, -$433.0 million in Q4 2025, and -$765.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.50 Bn | 631.74 Bn | 17.26 Bn | -479.00 Mn |
| 2 | AbbVie | 469.68 Bn | 463.11 Bn | 12.70 Bn | -195.00 Mn |
| 3 | Merck | 375.54 Bn | 368.40 Bn | 12.21 Bn | -544.00 Mn |
| 4 | Novartis Ag | 303.20 Bn | 295.51 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.76 Bn | 252.86 Bn | 12.86 Bn | - |
| 6 | Amgen | 236.70 Bn | 222.71 Bn | 7.24 Bn | -291.00 Mn |
| 7 | Gilead Sciences | 182.32 Bn | 179.14 Bn | 6.22 Bn | -587.00 Mn |
| 8 | Pfizer | 159.56 Bn | 147.86 Bn | 10.94 Bn | -1.32 Bn |
| 9 | Gsk | 106.15 Bn | 101.98 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.17 Bn | 47.79 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | -1.32 Bn |
| Mar 29, 2026 | -12.00 Mn |
| Dec 31, 2025 | -433.00 Mn |
| Sep 28, 2025 | -765.00 Mn |
| Jun 29, 2025 | -272.00 Mn |
| Mar 30, 2025 | -663.00 Mn |
| Sep 29, 2024 | -1.71 Bn |
| Jun 30, 2024 | -783.00 Mn |
| Mar 31, 2024 | -441.00 Mn |
| Dec 31, 2023 | -1.86 Bn |
| Jul 2, 2023 | -873.00 Mn |
| Apr 2, 2023 | -598.00 Mn |
| Jul 3, 2022 | -1.14 Bn |
| Apr 3, 2022 | -2.32 Bn |
| Oct 3, 2021 | -3.61 Bn |
| Jul 4, 2021 | -66.00 Mn |
| Apr 4, 2021 | 203.00 Mn |
| Sep 27, 2020 | -735.00 Mn |
| Jun 28, 2020 | -49.00 Mn |
| Mar 29, 2020 | 82.00 Mn |